Literature DB >> 28427007

Novel and revisited approaches in antituberculosis drug discovery.

Jennifer Herrmann1, Jan Rybniker2, Rolf Müller3.   

Abstract

The increasing prevalence of multidrug-resistant Mycobacterium tuberculosis (Mtb) necessitates the discovery and development of novel drugs against tuberculosis. In this review, we focus on two recent approaches that led to the discovery of promising antitubercular compound classes: (I) Hits derived from large compound library screens are increasingly difficult to translate into clinical application; this in turn fostered the development of innovative screening methods. (II) An alternative strategy towards high-quality hits and leads is to evaluate chemically diverse scaffolds which can be found among natural products. The so-called rekindling and repurposing approaches were particularly fruitful in the last few years.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28427007     DOI: 10.1016/j.copbio.2017.03.023

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  9 in total

1.  Extremely Low Hit Rate in a Diverse Chemical Drug Screen Targeting Mycobacterium abscessus.

Authors:  Jakob J Malin; Sandra Winter; Edeltraud van Gumpel; Georg Plum; Jan Rybniker
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 2.  Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

Authors:  Adetomiwa A Adeniji; Kirsten E Knoll; Du Toit Loots
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-05       Impact factor: 4.813

3.  Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance.

Authors:  Luke Bown; Santosh K Srivastava; Brandon M Piercey; Clarissa K McIsaac; Kapil Tahlan
Journal:  J Membr Biol       Date:  2017-11-02       Impact factor: 1.843

Review 4.  Microbial esterases and ester prodrugs: An unlikely marriage for combating antibiotic resistance.

Authors:  Erik M Larsen; R Jeremy Johnson
Journal:  Drug Dev Res       Date:  2018-10-10       Impact factor: 4.360

5.  Characterization of Pyridomycin B Reveals the Formation of Functional Groups in Antimycobacterial Pyridomycin.

Authors:  Tingting Huang; Zihua Zhou; Maolong Wei; Lin Chen; Zhihong Xiao; Zixin Deng; Shuangjun Lin
Journal:  Appl Environ Microbiol       Date:  2022-02-02       Impact factor: 5.005

Review 6.  Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis.

Authors:  Michael A Reiche; Digby F Warner; Valerie Mizrahi
Journal:  Front Mol Biosci       Date:  2017-11-14

7.  Antimycobacterial, Enzyme Inhibition, and Molecular Interaction Studies of Psoromic Acid in Mycobacterium tuberculosis: Efficacy and Safety Investigations.

Authors:  Sherif T S Hassan; Miroslava Šudomová; Kateřina Berchová-Bímová; Shanmugaraj Gowrishankar; Kannan R R Rengasamy
Journal:  J Clin Med       Date:  2018-08-20       Impact factor: 4.241

Review 8.  Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.

Authors:  Saad Alghamdi; Shaheed Ur Rehman; Nashwa Talaat Shesha; Hani Faidah; Muhammad Khurram; Sabi Ur Rehman
Journal:  Molecules       Date:  2020-12-02       Impact factor: 4.411

9.  Identification of benzothiazones containing a hexahydropyrrolo[3,4-c]pyrrol moiety as antitubercular agents against MDR-MTB.

Authors:  Xican Ma; Bing Han; Aoyu Wang; Lu Yang; Menghao Huang; Kushan Chowdhury; Jian Gu; Kai Zhang; Kai Lv
Journal:  RSC Adv       Date:  2020-04-07       Impact factor: 4.036

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.